Facts for Analysts

Quote

anonymous

Guest
Starting this thread for analysts to consider the realities at Galderma as they go into earnings calls every quarter. Galderma is a very duplicitous organization. Disclaimer: you may see some folks who work at Galderma gaslight and say horrible things about folks who are trying to shed light to the world about the horrors of this place - this should tell you about the toxic culture and lack of focus on what matters - results and This should go against what Flemming and leadership tells you about great teams etc. on investor calls. culture is everything - and culture at Galderma is crap.
 
results are artifically inflated in the front half of the year by "phasing" and bringing revenue to the beginning. It leaves a huge gap to cover in Q3 and Q4. For Medical Aesthetics, we are selling to Mckesson who buys in advance and is called "sell in". That is not true demand though as the "sell out" from mckesson to the real customers doesnt match sell in. Currently everyone in the company on pins and needles in the US. Nemolizumab is not well prepared. Dermatologists are up in arms about the ill preparedness. There is no on eon the team that has launched a biologic, from top to bottom. Most of the team is new and the leader who prepared for the drug launch for the past two years after spending 200M dollars just quit and went to anotehr company. The team training the sales reps sucks. Operations are in shambles. There is a very basic marketing plan. There is a very inexperienced medical team. Dermatological skincare - cetaphil is doing better than the first quarter but its still getting crushed by Cerave. We have some shelf commitments from big retailers in Q3 but still not enough to compete with the big boys - you will probably hear Flemming tout this but dont fall for it. Alastin is a non factor and very small - leadership at Alastin is really bad.
 
anonymous said:
Starting this thread for analysts to consider the realities at Galderma as they go into earnings calls every quarter. Galderma is a very duplicitous organization. Disclaimer: you may see some folks who work at Galderma gaslight and say horrible things about folks who are trying to shed light to the world about the horrors of this place - this should tell you about the toxic culture and lack of focus on what matters - results and This should go against what Flemming and leadership tells you about great teams etc. on investor calls. culture is everything - and culture at Galderma is crap.
Click to expand...
this is a great resource. I know quite a few bankers that cover the space and if this thread have frequent content I am happy to direct them here so they can do their own diligence after reading stuff
 
Bankers really don’t think much of clueless sales reps trying to be a simple analysis of the business. You little people are cunning and amusing.

Not we the bankers are convinced there is a talent and quality issue in the sales farce.
 
anonymous said:
Bankers really don’t think much of clueless sales reps trying to be a simple analysis of the business. You little people are cunning and amusing.

Not we the bankers are convinced there is a talent and quality issue in the sales farce.
Click to expand...
Are u sure? You’re clearly a very intelligent person and understand that sales teams generate revenue. You also acknowledge there’s a sales talent problem. That is hard to fix given the culture of the company. As a result you can’t expect stellar execution -> lower revenue -> stock price lower. Sales team is the main channel for generating revenue. Appreciate the input.
 
anonymous said:
You all not are a sales team. You’re mobile billboards with sound.
Click to expand...
You make a fair point. To some extent I agree. Field force is one of the most expensive asset Galderma has carrying costs on the balance sheet. And if we are pegging on the sales team (per you Mobile billboards) then analysts should see that there isnt much in the way of pegging hopes to excellence in execution that Flemming keeps talking about. Appreciate the input - these points will make the argument stronger that there is a substantial downgrade required in the stock price. Talent at Galderma is not good so I agree how can the execution be good. One way to showcase a turnaround is to show a substantial and swift turnaround initiative at Galderma led by leaders and HR. All big companies do it because they are structured and reputable. Can Galderma do this? If so, it might win brownie point with investors. Lower cost higher revenue.
 
anonymous said:
results are artifically inflated in the front half of the year by "phasing" and bringing revenue to the beginning. It leaves a huge gap to cover in Q3 and Q4. For Medical Aesthetics, we are selling to Mckesson who buys in advance and is called "sell in". That is not true demand though as the "sell out" from mckesson to the real customers doesnt match sell in. Currently everyone in the company on pins and needles in the US. Nemolizumab is not well prepared. Dermatologists are up in arms about the ill preparedness. There is no on eon the team that has launched a biologic, from top to bottom. Most of the team is new and the leader who prepared for the drug launch for the past two years after spending 200M dollars just quit and went to anotehr company. The team training the sales reps sucks. Operations are in shambles. There is a very basic marketing plan. There is a very inexperienced medical team. Dermatological skincare - cetaphil is doing better than the first quarter but its still getting crushed by Cerave. We have some shelf commitments from big retailers in Q3 but still not enough to compete with the big boys - you will probably hear Flemming tout this but dont fall for it. Alastin is a non factor and very small - leadership at Alastin is really bad.
Click to expand...
This post is very accurate and reflects what is happening at Galderma. High employee attrition rate, lack of culture (destroyed early on by Flemming), empty pipelines, poor US performance, aesthetic business driven by sell-in rather than sell-out (trade loading), generic Rx derm business, fierce competitive landscape in skincare, poor nemolizumab launch preparedness. Galderma used to be a company with huge potential.
Analysts, don’t believe everything Flemming tells you.
 
anonymous said:
Bankers really don’t think much of clueless sales reps trying to be a simple analysis of the business. You little people are cunning and amusing.

Not we the bankers are convinced there is a talent and quality issue in the sales farce.
Click to expand...
Reddit is a classic example of how bankers and analysts are scraping information from websites to make more informed decisions since it adds another layer of data that cannot be captured in corporate speak / presentations
 
anonymous said:
This post is very accurate and reflects what is happening at Galderma. High employee attrition rate, lack of culture (destroyed early on by Flemming), empty pipelines, poor US performance, aesthetic business driven by sell-in rather than sell-out (trade loading), generic Rx derm business, fierce competitive landscape in skincare, poor nemolizumab launch preparedness. Galderma used to be a company with huge potential.
Analysts, don’t believe everything Flemming tells you.
Click to expand...
Please read this! So true. Someone shared what cannot be voiced or spoken about openly. Most of us would be able to endorse everything in this post.
 
anonymous said:
results are artifically inflated in the front half of the year by "phasing" and bringing revenue to the beginning. It leaves a huge gap to cover in Q3 and Q4. For Medical Aesthetics, we are selling to Mckesson who buys in advance and is called "sell in". That is not true demand though as the "sell out" from mckesson to the real customers doesnt match sell in. Currently everyone in the company on pins and needles in the US. Nemolizumab is not well prepared. Dermatologists are up in arms about the ill preparedness. There is no on eon the team that has launched a biologic, from top to bottom. Most of the team is new and the leader who prepared for the drug launch for the past two years after spending 200M dollars just quit and went to anotehr company. The team training the sales reps sucks. Operations are in shambles. There is a very basic marketing plan. There is a very inexperienced medical team. Dermatological skincare - cetaphil is doing better than the first quarter but its still getting crushed by Cerave. We have some shelf commitments from big retailers in Q3 but still not enough to compete with the big boys - you will probably hear Flemming tout this but dont fall for it. Alastin is a non factor and very small - leadership at Alastin is really bad.
Click to expand...
I support this post too. McKesson is a ticking time bombe as there is not enough demand to get all the inventory sold.
 
I really hope that analysts (bankers, PE firms, valuation firms, anyone) reads this about us and other aesthetics companies. They have destroyed a good industry and now employees are left to reinvent themselves. Way to go FO and sycophants! Your claim to shame: destroyed many lives and families
 
anonymous said:
I really hope that analysts (bankers, PE firms, valuation firms, anyone) reads this about us and other aesthetics companies. They have destroyed a good industry and now employees are left to reinvent themselves. Way to go FO and sycophants! Your claim to shame: destroyed many lives and families
Click to expand...
Whenever started this thread is a genius. This is our chance to tell the world about the mismanagement and lies. Bankers have increasingly started scraping these sites and using AI to factor it into their models
 
anonymous said:
Great work, detective. You know this is SOP and has been happening since 2004, right? It’s adorable that you just found out but this isn’t a news flash.
Click to expand...
It happened under Umberto Antunes too, yes. But it is not SOP. And I should know, as I was brought it to clean up the trade loading / stock in trade mess when Galderma’s growth came crashing first time. Under Nestle ownership trade loading was a sackable offense. Many of us spent years cleaning the mess up. Everything we did under Stuart’s leadership to run a healthy business was destroyed by Flemming and the EQT greed to generate (fake) growth at any cost.
 
anonymous said:
It happened under Umberto Antunes too, yes. But it is not SOP. And I should know, as I was brought it to clean up the trade loading / stock in trade mess when Galderma’s growth came crashing first time. Under Nestle ownership trade loading was a sackable offense. Many of us spent years cleaning the mess up. Everything we did under Stuart’s leadership to run a healthy business was destroyed by Flemming and the EQT greed to generate (fake) growth at any cost.
Click to expand...
Factual and truthful reply. Great to see that others share the same perspective on what has been going on at Galderma.
 
anonymous said:
It happened under Umberto Antunes too, yes. But it is not SOP. And I should know, as I was brought it to clean up the trade loading / stock in trade mess when Galderma’s growth came crashing first time. Under Nestle ownership trade loading was a sackable offense. Many of us spent years cleaning the mess up. Everything we did under Stuart’s leadership to run a healthy business was destroyed by Flemming and the EQT greed to generate (fake) growth at any cost.
Click to expand...
This should be reposted every single say so it is not forgotten
 
Top Bottom
Back
Quote